Literature DB >> 18358680

Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.

Stefano Fanti1, Valentina Ambrosini, Paola Tomassetti, Paolo Castellucci, Giancarlo Montini, Vincenzo Allegri, Gaia Grassetto, Domenico Rubello, Cristina Nanni, Roberto Franchi.   

Abstract

(18)F-FDG PET value for the assessment of neuroendocrine tumours (NET) is limited. Preliminary studies indicate that somatostatin receptor PET using (68)Ga-DOTA-peptides is more accurate for disease assessment and provide additional data on receptor status, that are crucial for targeted radionuclide therapy. At present, however, few papers investigated the role of (68)Ga-DOTA-NOC PET in NET, especially in unusual situations. The purpose of the present study was to evaluate (68)Ga-DOTA-NOC for the evaluation of NET of uncommon presentation. Patients with biopsy-proven NET were scheduled for (68)Ga-DOTA-NOC PET; we excluded from further evaluation cases with most common NET tumours (gastro-entero-pancreatic and pulmonary localization of primary lesion, MEN syndromes, medullary thyroid carcinoma, pheochromocytomas). PET results were compared with findings of conventional imaging, including CT, ultrasonography, MR and somatostatin receptor scintigraphy; finally PET results were compared with follow-up data with respect to the impact on patient management. Fourteen patients were finally enrolled; primary tumours were located at uterine level (3 cases), prostate (3 cases), ovary (1 case), kidney (1 case), breast (1 case), ear (1 case); also 3 cases of paraganglioma (at neck, abdominal and mediastinum level) and 1 case of lymphoma were included. (68)Ga-DOTA-NOC PET was positive, showing at least 1 lesion, in 6/14 cases while 5 cases turned out negative and 2 inconclusive. On a clinical basis, (68)Ga-DOTA-NOC provided additional information in comparison to conventional imaging procedures in 7/14 cases, and was considered useful in 12/14 patients, with 8 patients in which (68)Ga-DOTA-NOC PET was determinant for patient's management. Although the number of patients studied is limited, our data show that (68)Ga-DOTA-NOC can be usefully applied for the evaluation of NET of uncommon presentation; in particular very promising results were obtained in paraganglioma. On the other hand, care has to be paid when studying lesions localized at sites of physiological concentration of the tracer, and in presence of inflammation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18358680     DOI: 10.1016/j.biopha.2008.01.010

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  20 in total

Review 1.  ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

Authors:  Valentina Ambrosini; Davide Campana; Paola Tomassetti; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

Authors:  Yodphat Krausz; Nanette Freedman; Rina Rubinstein; Efraim Lavie; Marina Orevi; Sagi Tshori; Asher Salmon; Benjamin Glaser; Roland Chisin; Eyal Mishani; David J Gross
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

Review 3.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

4.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

5.  Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?

Authors:  Giorgio Treglia; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12       Impact factor: 9.236

Review 6.  ⁶⁸Ga-labelled peptides in the management of neuroectodermal tumours.

Authors:  Meeran Naji; Adil AL-Nahhas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 7.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

Review 8.  Clinical applications of Gallium-68.

Authors:  Sangeeta Ray Banerjee; Martin G Pomper
Journal:  Appl Radiat Isot       Date:  2013-02-20       Impact factor: 1.513

9.  Imaging in neuroendocrine tumors: an update for the clinician.

Authors:  Jessica E Maxwell; James R Howe
Journal:  Int J Endocr Oncol       Date:  2015

10.  Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.

Authors:  Henri J L M Timmers; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Bastiaan Havekes; Graeme Eisenhofer; Lucia Martiniova; Karen T Adams; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2009-10-28       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.